Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | CCR6 | P51684 | 7/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2709218 | 1.00 | DPP4 (0.53) | DPP4DPP8DPP9IRAK4CCR6 | |
| SCHEMBL2709196 | 0.90 | DPP4 (0.58) | DPP4DPP8DPP9IRAK4CCR6 | |
| SCHEMBL2711015 | 0.85 | DPP4 (0.60) | DPP4DPP8DPP9IRAK4 | |
| SCHEMBL2709114 | 0.85 | DPP4 (0.60) | DPP4DPP8DPP9IRAK4 | |
| SCHEMBL2709194 | 0.84 | DPP4 (0.56) | DPP4DPP8DPP9 | |
| SCHEMBL2709957 | 0.83 | DPP4 (0.48) | DPP4 | |
| SCHEMBL2709867 | 0.82 | DPP4 (0.49) | DPP4 | |
| SCHEMBL2710061 | 0.82 | DPP4 (0.58) | DPP4DPP8DPP9 | |
| SCHEMBL2708439 | 0.81 | DPP4 (0.49) | DPP4DPP8DPP9IRAK4 | |
| SCHEMBL2711201 | 0.80 | ALDH1A1 (0.43) | DPP4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.